C. London

C. London, S. Weisbrode, V. Samii, 2012, Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association.

Canine osteosarcoma: a naturally occurring disease to inform pediatric oncology.

W. Kisseberth, C. London, J. Fenger, 2014, ILAR journal.

A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma

C. London, H. Gardner, Juan Peng, 2016, BMC Veterinary Research.

Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review.

E. Keller, W. Kisseberth, C. London, 1994, Journal of drug targeting.

Treatment of canine mast cell tumors with CCNU (lomustine).

C. London, A. Moore, L. Williams, 1999, Journal of veterinary internal medicine.

Biological activity of dihydroartemisinin in canine osteosarcoma cell lines.

C. Couto, W. Kisseberth, C. London, 2008, American journal of veterinary research.

Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma.

C. Couto, W. Kisseberth, C. London, 2007, Journal of veterinary internal medicine.

Comparison o f C OAP a nd U W-19 Protocols f or Dogs with Multicentric L ymphoma

W. Kisseberth, C. London, L. Lord, 2007 .

Cutaneous Mast Cell Tumors

C. London, M. Wellman, 2020 .

Mast cell tumors in the dog.

B. Séguin, C. London, 2003, The Veterinary clinics of North America. Small animal practice.

Activating mutations in the catalytic or juxtamembrane domain of c-kit in splenic mast cell tumors of cats.

C. London, May Chien, G. Dank, 2002, American journal of veterinary research.

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma

J. Byrd, K. Coombes, A. Johnson, 2016, PloS one.

Comparison of high-dose intermittent and low-dose continuous oral artemisinin in dogs with naturally occurring tumors.

C. Couto, M. Phelps, J. Dalton, 2014, Journal of the American Animal Hospital Association.

Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors.

D. Thamm, C. London, A. Avery, 2012, Journal of veterinary internal medicine.

Detection of c-kit Mutations in Canine Mast Cell Tumors using Fluorescent Polyacrylamide Gel Electrophoresis

L. Lyons, C. London, R. Grahn, 2004, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc.

Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs.

C. London, P. Kass, May Chien, 2002, American journal of veterinary research.

Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit.

S. Galli, C. London, S. Helfand, 1999, Experimental hematology.

Electrophoresis Mutations in Canine Mast Cell Tumors using Fluorescent Polyacrylamide Gel kit Detection of c

L. Lyons, C. London, R. Grahn, 2011 .

A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors.

C. Rodriguez, C. London, I. Gordon, 2008, Journal of veterinary internal medicine.

Comparison of thoracic radiographs and single breath-hold helical CT for detection of pulmonary nodules in dogs with metastatic neoplasia.

S. Nemanic, E. Wisner, C. London, 2006, Journal of veterinary internal medicine.

Evaluation of dogs and cats with tumors of the ear canal: 145 cases (1978-1992).

G. Ogilvie, A. Norris, D. McCaw, 1996, Journal of the American Veterinary Medical Association.

Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma

W. Kisseberth, C. London, D. Russell, 2012, BMC Veterinary Research.

Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.

N. Shenoy, G. Mcmahon, J. Cherrington, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma--a multicenter randomized double-blind study.

R. Dubielzig, C. Rodriguez, B. Madewell, 1995, Cancer biotherapy.

Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON

Amanda R. Campbell, B. Ramaswamy, Lianbo Yu, 2018, Cancer Immunology Research.

Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.

D. Thamm, C. London, D. Vail, 2012, Veterinary and comparative oncology.

Biological activity of toceranib (Palladia) in canine anal gland anal SAC adenocarcinoma (AGASACA)

R. M. Gamblin, D. Thamm, C. London, 2011 .

Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.

N. Pryer, Leslie B. Lee, J. Cherrington, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma.

M. Ritter, W. Kisseberth, C. London, 1996, Experimental hematology.

Improving cancer drug discovery by studying cancer across the tree of life.

J. Thorne, W. Eward, A. Boddy, 2019, Molecular biology and evolution.

Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study.

C. London, D. Vail, I. Kurzman, 2012, Veterinary and comparative oncology.

The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.

K. Foley, J. Barsoum, M. Bear, 2008, Experimental hematology.

Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis.

J. Tschopp, A. Abbas, Y. Refaeli, 1998, Immunity.

The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines

Jiayuh Lin, S. Fossey, M. Bear, 2011, BMC Cancer.

Classical NF-κB Metabolically Reprograms Sarcoma Cells Through Regulation of Hexokinase 2

P. Houghton, D. Guttridge, Priya Londhe, 2018, Front. Oncol..

6.2. Kinase Dysfunction and Kinase Inhibitors

C. London, 2013 .

Kinase dysfunction and kinase inhibitors.

C. London, 2013, Veterinary dermatology.

Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study

M. Pennell, D. Thamm, C. London, 2015, PloS one.

Alternating carboplatin and doxorubicin as adjunctive chemotherapy to amputation or limb-sparing surgery in the treatment of appendicular osteosarcoma in dogs.

B. Séguin, C. London, M. Kent, 2004, Journal of veterinary internal medicine.

Alternating Carboplatin and Doxorubicin as Adjunctive Chemotherapy to Amputation or Limb-Sparing Surgery in the Treatment of Appendicular Osteosarcoma in Dogs

B. Séguin, C. London, M. Kent, 2004 .

Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma

D. Thamm, C. London, D. Vail, 2018, Veterinary and comparative oncology.

Comparison of thoracic radiographs and single breath-hold helical CT for detection of pulmonary nodules in dogs with metastatic neoplasia.

S. Nemanic, E. Wisner, C. London, 2006, Journal of veterinary internal medicine.

Guiding the Optimal Translation of New Cancer Treatments From Canine to Human Cancer Patients

S. Hirschfeld, C. Khanna, C. London, 2009, Clinical Cancer Research.

Dog Models of Naturally Occurring Cancer

C. E. Alvarez, I. Zapata, W. Kisseberth, 2016 .

MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines

C. London, J. Fenger, Xiaoli Zhang, 2018, PloS one.

Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2

Winnie S. Liang, J. Trent, P. Houghton, 2019, Communications Biology.

Genome-wide analyses implicate 33 loci in heritable dog osteosarcoma , including regulatory variants near CDKN 2 A / B

K. Lindblad-Toh, E. Lander, C. Howald, 2013 .

Identification of a novel germline MET mutation in dogs.

A. Liao, C. London, M. McMahon, 2006, Animal genetics.

Characterization, expression and function of c-Met in canine spontaneous cancers.

A. Liao, C. London, M. McMahon, 2005, Veterinary and comparative oncology.

Perspectives from man’s best friend: National Academy of Medicine’s Workshop on Comparative Oncology

Mark Dewhirst, Daniel L. Gustafson, Deborah W. Knapp, 2016, Science Translational Medicine.

Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic sarcomas of dogs.

P. Moore, A. Liao, C. London, 2006, American journal of veterinary research.

Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose

M. Pennell, W. Kisseberth, C. London, 2013, BMC Veterinary Research.

KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells

G. Mcmahon, K. L. La Perle, R. Gedrich, 2016, Clinical Cancer Research.

NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma

James H. Doroshow, Amy LeBlanc, Yves Pommier, 2018, Clinical Cancer Research.

Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.

N. Shenoy, G. Mcmahon, J. Cherrington, 2002, Blood.

Expression of Bcl-XL Restores Cell Survival, but Not Proliferation and Effector Differentiation, in Cd28-Deficient T Lymphocytes

C. Klein, R. Mulligan, A. Abbas, 2000, The Journal of experimental medicine.

Plasma cytokeratin‐18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib

C. London, J. Fenger, E. Warry, 2018, Journal of veterinary internal medicine.

Small molecule inhibitors in veterinary oncology practice.

C. London, 2014, The Veterinary clinics of North America. Small animal practice.

Lomustine (CCNU) for the treatment of resistant lymphoma in dogs.

C. London, A. Moore, L. Williams, 1999, Journal of veterinary internal medicine.

22 Breed-specific Canine Lymphoproliferative Diseases

J. Modiano, M. Breen, C. London, 2006 .

In vitro Canine Distemper Virus Infection of Canine Lymphoid Cells: A Prelude to Oncolytic Therapy for Lymphoma

B. Madewell, S. Suter, R. Cattaneo, 2005, Clinical Cancer Research.

Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study

M. Pennell, J. Modiano, D. Ito, 2014, PloS one.

Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs

T. Fan, S. Suter, C. Khanna, 2021, Clinical Cancer Research.

MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines

J. Modiano, M. Bear, W. Kisseberth, 2016, BMC Cancer.

A functional comparison of canine and murine bone marrow derived cultured mast cells.

C. London, Tzu-yin Lin, 2006, Veterinary immunology and immunopathology.

Generation and characterization of bone marrow-derived cultured canine mast cells.

C. London, L. Rush, Tzu-yin Lin, 2006, Veterinary immunology and immunopathology.

Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis

S. Kulp, J. Modiano, W. Kisseberth, 2017, BMC Cancer.

Functional Responses and Costimulator Dependence of Memory CD4+ T Cells1

A. Abbas, C. London, Michael P. Lodge, 2000, The Journal of Immunology.

The addition of metronomic chemotherapy does not improve outcome for canine splenic haemangiosarcoma

C. London, H. Gardner, K. Cronin, 2018, The Journal of small animal practice.

Functional characteristics and survival requirements of memory CD4+ T lymphocytes in vivo.

A. Abbas, C. London, V. Perez, 1999, Journal of immunology.

Abstract 1744: ACP-196: A second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma

J. Byrd, A. Johnson, W. Kisseberth, 2014 .

Helper T cell subsets: heterogeneity, functions and development.

A. Kelso, A. Abbas, C. London, 1998, Veterinary immunology and immunopathology.

Suppression of canine myeloid cells by soluble factors from cultured canine tumor cells.

J. Wasserman, W. Carson, C. London, 2012, Veterinary immunology and immunopathology.

The role of small molecule inhibitors for veterinary patients.

C. London, 2007, The Veterinary clinics of North America. Small animal practice.

Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines

M. Bear, W. Kisseberth, C. London, 2014, BMC Veterinary Research.

Use of kit internal tandem duplications to establish mast cell tumor clonality in 2 dogs.

C. London, May Chien, R. Zavodovskaya, 2004, Journal of veterinary internal medicine.

Characterization of STAT3 expression, signaling and inhibition in feline oral squamous cell carcinoma

T. Rosol, M. Bear, W. Kisseberth, 2015, BMC Veterinary Research.

Prevalence of elevated alanine transaminase activity in dogs treated with CCNU (Lomustine)*.

C. Couto, W. Kisseberth, C. London, 2009, Veterinary and comparative oncology.

IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis.

P. Houghton, X. Mo, H. Bid, 2018, JCI insight.

Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines

S. Kulp, Jiayuh Lin, M. Bear, 2012, BMC Veterinary Research.

A Mouse Model of Activating Met Mutations

G. Woude, C. London, C. Graveel, 2005, Cell cycle.

Identification of Genetic Susceptibility Factors Associated with Canine Gastric Dilatation-Volvulus

V. Zismann, I. Piras, W. Hendricks, 2020, Genes.

Safety and efficacy of targeted hyperthermia treatment utilizing gold nanorod therapy in spontaneous canine neoplasia

C. London, H. Gardner, Christiane Schoen, 2017, BMC Veterinary Research.

ΔNp63 mediates cellular survival and metastasis in canine osteosarcoma

D. Guttridge, C. London, H. Gardner, 2016, OncoTarget.

miR-29 Acts as a Decoy in Sarcomas to Protect the Tumor Suppressor A20 mRNA from Degradation by HuR

C. Croce, C. Keller, P. Houghton, 2013, Science Signaling.

Comparison of harmonic blade versus traditional approach in canine patients undergoing spinal decompressive surgery for naturally occurring thoracolumbar disk extrusion

G. Fosgate, C. London, B. Hettlich, 2017, PloS one.

Overexpression of miR-9 in mast cells is associated with invasive behavior and spontaneous metastasis

S. Volinia, M. Bear, W. Kisseberth, 2014, BMC Cancer.

Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma

P. Houghton, Jiayuh Lin, Hui Xiao, 2017, PloS one.

MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines

J. Modiano, M. Bear, W. Kisseberth, 2016, BMC Cancer.

Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2

Winnie S. Liang, J. Trent, P. Houghton, 2019, Communications Biology.

Overexpression of miR-9 in mast cells is associated with invasive behavior and spontaneous metastasis

S. Volinia, M. Bear, W. Kisseberth, 2014, BMC Cancer.

Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma.

J. Byrd, M. Phelps, X. Mo, 2017, Veterinary and comparative oncology.

Abstract LB-232: Preliminary results of a phase I study of the novel CRM1 inhibitors KPT-276 and KPT-335 in dogs with spontaneous cancer

W. Kisseberth, C. London, L. Plamondon, 2012 .

The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma

P. Houghton, Jiayuh Lin, D. Guttridge, 2016, Molecular Cancer Therapeutics.

The effects of preoperative oral administration of carprofen or tramadol on postoperative analgesia in dogs undergoing cutaneous tumor removal.

C. London, H. Gardner, Nicole M Karrasch, 2015, The Canadian veterinary journal = La revue veterinaire canadienne.

Kinase inhibitors in cancer therapy.

C. London, C. London, 2004, Veterinary and comparative oncology.

A novel small molecule Met inhibitor, PF2362376, exhibits biological activity against osteosarcoma.

J. Christensen, A. Liao, J. McCleese, 2007, Veterinary and comparative oncology.

Erratum: miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR (Science Signaling (2013) 6 (er6))

C. Croce, C. Keller, P. Houghton, 2013 .

Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document.

D. Thamm, C. London, D. Vail, 2015, Veterinary and comparative oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Guiding the Optimal Translation of New Cancer Treatments From Canine to Human Cancer Patients

S. Hirschfeld, C. Khanna, C. London, 2009, Clinical Cancer Research.

The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma

P. Houghton, Jiayuh Lin, D. Guttridge, 2016, Molecular Cancer Therapeutics.

A novel small molecule Met inhibitor, PF2362376, exhibits biological activity against osteosarcoma.

J. Christensen, A. Liao, C. London, 2007, Veterinary and comparative oncology.

IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis.

P. Houghton, X. Mo, H. Bid, 2018, JCI insight.

KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells

G. Mcmahon, K. L. La Perle, R. Gedrich, 2016, Clinical Cancer Research.

Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.

N. Shenoy, G. Mcmahon, J. Cherrington, 2002, Blood.

Abstract LB-308: KPT-9274 inhibits cellular NAD and synergizes with doxorubicin to treat dogs with lymphoma

E. Baloglu, C. London, W. Senapedis, 2017 .

Abstract 4700: The novel and selective PI3Kδ inhibitor, RV1001, displays single agent biologic activity in spontaneous canine NHL

C. London, S. Viswanadha, Kumar V. Penmetsa, 2015 .